跳转至内容
Merck
CN
所有图片(1)

文件

AB16661

Sigma-Aldrich

Anti-PARP Poly ADP-ribose Polymerase-1 Antibody

serum, Chemicon®

登录查看公司和协议定价

别名:
Poly [ADP-ribose] polymerase 1, PARP-1, NAD(+) ADP-ribosyltransferase 1, ADPRT 1, Poly[ADP-ribose] synthase 1, ARTD1
UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

rabbit

质量水平

抗体形式

serum

抗体产品类型

primary antibodies

克隆

polyclonal

种属反应性

rat, human, bovine, mouse

制造商/商品名称

Chemicon®

技术

ELISA: suitable
western blot: suitable

NCBI登记号

UniProt登记号

运输

dry ice

靶向翻译后修饰

unmodified

基因信息

bovine ... Parp1(286764)
human ... PARP1(142)
mouse ... Parp1(11545)
rat ... Parp1(25591)

特异性

Recognizes 116 kDa PARP-1 and the 85 kDa apoptosis-related cleavage fragment.

免疫原

Synthetic peptide based on the sequence from the C-terminal portion of the bovine PARP automodification domain (amino acids 509-524) conjugated to a carrier.

应用

Research Category
Apoptosis & Cancer

Metabolism
Research Sub Category
Apoptosis - Additional

Enzymes & Biochemistry
This Anti-PARP Poly ADP-ribose Polymerase-1 Antibody is validated for use in ELISA, WB for the detection of PARP Poly ADP-ribose Polymerase-1.
Western blot: 1:500 using alkaline phosphatase.

ELISA

Optimal working dilutions must be determined by end user.

联系

Replaces: 04-575; 04-576

外形

Antiserum containing 0.05% sodium azide. Liquid containing 0.05% sodium azide.

储存及稳定性

Maintain frozen at -20°C in undiluted aliquots for up to 12 months.

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lauren K Jillson et al.
Molecular cancer research : MCR, 19(7), 1123-1136 (2021-04-14)
Prostate cancer genomic subtypes that stratify aggressive disease and inform treatment decisions at the primary stage are currently limited. Previously, we functionally validated an aggressive subtype present in 15% of prostate cancer characterized by dual deletion of MAP3K7 and CHD1.
Kwang Il Park et al.
Oncology letters, 13(4), 2521-2530 (2017-04-30)
Lonicera japonica Thunb. (L. japonica T.) has historically been used in Korean herbal medicine due to its anticancer and protective effects on the respiratory system. In the present study, the polyphenolic compounds in L. japonica T. were investigated using high-performance
Marlena Zyśk et al.
International journal of molecular sciences, 21(22) (2020-11-18)
The N-acetylaspartate network begins in neurons with N-acetylaspartate production catalyzed by aspartate N-acetyltransferase from acetyl-CoA and aspartate. Clinical studies reported a significant depletion in N-acetylaspartate brain level in type 1 diabetic patients. The main goal of this study was to
Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification.
Svedlund, J; Koskinen Edblom, S; Marquez, VE; ?kerstrom, G; Bjorklund, P; Westin, G
The Journal of clinical endocrinology and metabolism null
Jessica Svedlund et al.
Endocrine-related cancer, 21(2), 231-239 (2013-12-03)
Primary hyperparathyroidism (pHPT) resulting from parathyroid tumors is a common endocrine disorder with incompletely understood etiology. In renal failure, secondary hyperparathyroidism (sHPT) occurs with multiple tumor development as a result of calcium and vitamin D regulatory disturbance. The aim of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门